| Literature DB >> 30225268 |
Golnaz Azami1,2, Kim Lam Soh1, Shariff Ghazali Sazlina3, Md Said Salmiah4, Sanaz Aazami2, Mosayeb Mozafari2, Hamid Taghinejad2.
Abstract
In recent years, great emphasis has been placed on the role of nonpharmacological self-management in the care of patients with diabetes. Studies have reported that nurses, compared to other healthcare professionals, are more likely to promote preventive healthcare seeking behaviors. The aim of this study was to investigate the effectiveness of a nurse-led diabetes self-management education on glycosylated hemoglobin. A two-arm parallel-group randomized controlled trial with the blinded outcome assessors was designed. One hundred forty-two adults with type 2 diabetes were randomized to receive either usual diabetes care (control group) or usual care plus a nurse-led diabetes self-management education (intervention group). Duration of the intervention was 12 weeks. The primary outcome was glycosylated hemoglobin (HbA1c values). Secondary outcomes were changes in blood pressure, body weight, lipid profiles, self-efficacy (efficacy expectation and outcome expectation), self-management behaviors, quality of life, social support, and depression. Outcome measures were assessed at baseline and at 12-week and 24-week postrandomizations. Patients in the intervention group showed significant improvement in HbA1c, blood pressure, body weight, efficacy expectation, outcome expectation, and diabetes self-management behaviors. The beneficial effect of a nurse-led intervention continued to accrue beyond the end of the trial resulting in sustained improvements in clinical, lifestyle, and psychosocial outcomes. This trial is registered with IRCT2016062528627N1.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30225268 PMCID: PMC6129337 DOI: 10.1155/2018/4930157
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Figure 1Consort flow diagram of study participation.
Sociodemographic characteristics of study participants.
| Characteristics | Total sample | Intervention group | Control group |
|---|---|---|---|
| Age, yearsa | 56 ± 11.1 | 55.09 ± 10.16 | 53.49 ± 10.98 |
| Genderb | |||
| (i) Male | 49 (34%) | 23 (32.4%) | 26 (36.6%) |
| (ii) Female | 93 (65.5%) | 48 (67.6%) | 45 (63.4%) |
| Marital statusb | |||
| (i) Married | 117 (82.4%) | 58 (81.7%) | 59 (83.1%) |
| (ii) Single (divorced/widow) | 25 (17.6%) | 13 (18.3%) | 12 (16.9%) |
| Educational statusb | |||
| (i) Primary education | 64 (45.1%) | 33 (46.5%) | 31 (43.7%) |
| (ii) Secondary education | 23 (16.2%) | 12 (16.9%) | 11 (15.5%) |
| (iii) Tertiary education | 55 (38.7%) | 26 (36.6%) | 29 (40.8%) |
| Occupation statusb | |||
| (i) Working | 83 (58.5%) | 28 (39.4%) | 31 (43.7%) |
| (ii) Not working | 59 (41.5%) | 43 (60.6%) | 40 (56.3%) |
| Difficulty paying for basicsb | |||
| (i) Very hard | 7 (4.9%) | 5 (7%) | 2 (2.8%) |
| (ii) Somewhat hard | 96 (67.6%) | 47 (66.2%) | 49 (69%) |
| (iii) Not hard at all | 39 (27.5%) | 19 (26.8%) | 20 (28.2%) |
| Smoking statusb | |||
| (i) Current smoker | 18 (12.7%) | 9 (12.7%) | 9 (12.7%) |
| (ii) Never | 108 (76.1%) | 55 (77.5%) | 53 (74.6%) |
| (iii) Ex-smoker | 16 (11.3%) | 7 (9.9%) | 9 (12.7%) |
| Duration of diabetes, yearsa | 8.9 ± 7.4 | 8.8 ± 7.5 | 9.04 ± 7.31 |
| Presence of at least one comorbidityb | 113 (79.5%) | 57 (80.3%) | 56 (78.9%) |
| Use of SBGMa | 71 (50%) | 32 (45.1%) | 39 (54.9%) |
| BMI (kg/m2)a | 28.78 ± 3.34 | 28.69 ± 3.25 | 28.87 ± 3.46 |
| Systolic blood pressure (mmHg)a | 132.3 ± 11.2 | 130.6 ± 9.6 | 133.9 ± 12.4 |
| Diastolic blood pressure (mmHg)a | 86.6 ± 5.9 | 85.8 ± 5.2 | 87.3 ± 6.4 |
| HbA1ca | 9.32 ± 1.11 | 9.32 ± 1.06 | 9.31 ± 1.15 |
| (i) 8–8.9%b | 59 (41.5%) | 29 (40.8%) | 30 (42.3%) |
| (ii) ≥9%b | 83 (58.5%) | 42 (59.2%) | 41 (57.7%) |
| Triglyceridea | 142.4 ± 34.9 | 142.83 ± 34.4 | 142.09 ± 35.7 |
| Total cholesterola | 172.5 ± 46.8 | 173.14 ± 45.4 | 171.91 ± 48.4 |
| HDLa | 53.44 ± 12.62 | 53.68 ± 12.8 | 53.21 ± 12.4 |
| LDLa | 94.28 ± 27.86 | 95.89 ± 30 | 92.68 ± 25.6 |
Note: aMean ± standard deviation; bfrequency (%); HDL = high-density lipoprotein; LDL = low-density lipoprotein; BMI = body mass index; SBMG = self-blood glucose monitoring.
Two-way ANOVA with repeated measures for primary and secondary outcomes.
| Model | Intervention mean (SD) | Control mean (SD) | Significance | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| Effect size (Eta square) | |
|
| 9.3 (1.06) | 8.6 (1.01) | 7.9 (0.93) | 9.3 (1.1) | 9.3 (1.1) | 9.3 (1.1) | |||
| Group | 14.5 |
| 0.09 | ||||||
| Time | 277.6 |
| 0.66 | ||||||
| Group × time | 289.5 |
| 0.67 | ||||||
|
| 130.7 (9.4) | 129.3 (9.1) | 127.8 (9) | 133.9 (12.3) | 133.7 (12.1) | 133.3 (12) | |||
| Group | 5.9 | 0.01 | 0.04 | ||||||
| Time | 59.1 |
| 0.29 | ||||||
| Group × time | 25.7 |
| 0.15 | ||||||
|
| 85.8 (0.69) | 84.7 (0.67) | 83.4 (0.65) | 87.3 (0.69) | 87.3 (0.67) | 87.1 (0.65) | |||
| Group | 7.4 |
| 0.05 | ||||||
| Time | 61.3 |
| 0.30 | ||||||
| Group × time | 39.3 |
| 0.21 | ||||||
|
| 82.58 (11.08) | 82.21 (11.09) | 82 (10.89) | 83.75 (10.93) | 83.77 (10.91) | 83.82 (10.89) | |||
| Group | 0.68 | 0.41 | 0.01 | ||||||
| Time | 4.69 | 0.01 | 0.03 | ||||||
| Group × time | 7.17 | 0.01 | 0.04 | ||||||
|
| 28.69 (3.2) | 28.54 (3.2) | 28.55 (3.2) | 28.87 (3.4) | 28.87 (3.4) | 29.89 (3.4) | |||
| Group | 0.24 | 0.62 | 0.01 | ||||||
| Time | 2.59 | 0.07 | 0.01 | ||||||
| Group × time | 3.18 | 0.04 | 0.02 | ||||||
|
| 142.83 (34.4) | 141.66 (33.9) | 140.90 (33.7) | 142.09 (35.7) | 142.04 (35.6) | 142.01 (35.6) | |||
| Group | 0.00 | 0.96 | 0.01 | ||||||
| Time | 40.41 |
| 0.22 | ||||||
| Group × time | 33.82 |
| 0.19 | ||||||
|
| 173.1 (45.4) | 171.3 (43.8) | 169.09 (43.1) | 171.9 (48.4) | 170.7 (47.02) | 171.88 (46.8) | |||
| Group | 0.006 | 0.93 | 0.01 | ||||||
| Time | 3.15 | 0.06 | 0.02 | ||||||
| Group × time | 0.10 | 0.82 | 0.01 | ||||||
|
| 95.89 (30.04) | 95.59 (28.4) | 93.95 (27.9) | 92.68 (25.6) | 93.06 (25.4) | 94.15 (25) | |||
| Group | 0.16 | 0.68 | 0.01 | ||||||
| Time | 0.15 | 0.85 | 0.01 | ||||||
| Group × time | 5.62 | 0.22 | 0.39 | ||||||
|
| 53.68 (12.8) | 54.72 (11.6) | 55.38 (11.8) | 53.21 (12.4) | 53.21 (12.5) | 52.76 (12.6) | |||
| Group | 0.55 | 0.45 | 0.01 | ||||||
| Time | 2.66 | 0.28 | 0.01 | ||||||
| Group × time | 6.94 | 0.94 | 0.04 | ||||||
|
| 98.35 (13.95) | 113.47 (11.07) | 123.47 (11.31) | 98.06 (17.47) | 99.77 (14.48) | 98.44 (15.69) | |||
| Group | 34.3 |
| 0.19 | ||||||
| Time | 152.2 |
| 0.52 | ||||||
| Group × time | 138.7 |
| 0.49 | ||||||
|
| 57.80 (7.11) | 62.85 (5.50) | 66.79 (5.35) | 58.11 (7.50) | 58.04 (7.33) | 58.16 (7.23) | |||
| Group | 16.15 |
| 0.10 | ||||||
| Time | 150.81 |
| 0.51 | ||||||
| Group × time | 147.61 |
| 0.51 | ||||||
|
| 3.56 (1.22) | 4.67 (1) | 5.41 (1.15) | 3.71 (1.40) | 3.67 (1.37) | 3.73 (1.40) | |||
| Group | 16.7 |
| 0.10 | ||||||
| Time | 228.5 |
| 0.62 | ||||||
| Group × time | 221.6 |
| 0.61 | ||||||
|
| 50.42 (9.17) | 50.76 (9.06) | 50.67 (9.04) | 50.69 (8.90) | 50.34 (8.83) | 50.39 (8.71) | |||
| Group | 0.00 | 0.92 | 0.01 | ||||||
| Time | 0.07 | 0.86 | 0.01 | ||||||
| Group × time | 10.5 |
| 0.07 | ||||||
|
| 52.63 (9.31) | 54.33 (9.42) | 55.37 (9.61) | 55.83 (12.11) | 55.82 (12.63) | 55.91 (12.75) | |||
| Group | 0.88 | 0.34 | 0.01 | ||||||
| Time | 43.6 |
| 0.23 | ||||||
| Group × time | 39.3 |
| 0.21 | ||||||
|
| 12.15 (4.99) | 11.98 (4.97) | 11.95 (5.03) | 12.76 (4.66) | 12.84 (4.61) | 12.91 (4.50) | |||
| Group | 1 | 0.31 | 0.01 | ||||||
| Time | 0.51 | 0.55 | 0.01 | ||||||
| Group × time | 9.33 | 0.10 | 0.06 | ||||||
Note: Group: test of between-subject effects; Time: test of within-subject effect; Group × time: interaction between group by time; SD: standard deviation; T1: baseline measurement; T2: 3-month measurement; T3: 6-month measurement; DSMB: diabetes self-management behavior; LDL: low-density lipoprotein; HDL: high-density lipoprotein; BMI: body mass index; QOL: quality of life; Primary outcome: HbA1c. To interpret effect sizes, 0.02 be considered a “small magnitude,” 0.15 be considered a “medium magnitude,” and 0.35 be considered a “large magnitude” [52].